Atrandi
Scalable single-cell research platform
Vilnius, Lithuania
Atrandi is a precision medicine platform.
Only accessible to MedStartr community members.
Join nowHow We Help
Problem Statement
Current single-cell analysis methods limit scientific discovery and the development of new therapies.
Core Technology
microfluidics
Key Differentiators
Pioneering next-generation single-cell analysis technology; Semi-permeable capsule (SPC) technology
Clinical Focus
Oncology; Cell Therapy
Company Info
- Business Model
- Device Sales
- Founded
- 2016
- Total Funding
- Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now - Website
- atrandi.com/
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Published in Frontiers in Microbiology (2024) on high-throughput microbial sequencing. Used in Harvard Medical School research (Science publication). 150+ installations globally supporting eukaryotic/microbial genomics and high-throughput screening.
Only accessible to MedStartr community members.
Join nowWhat do you think of Atrandi?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now